激素敏感型、依赖型和难治型急性GVHD后慢性GVHD的发生率与临床结局
该回顾性单中心队列研究纳入2008至2016年间784例因血液系统恶性肿瘤接受异基因造血干细胞移植的成人和儿童患者,按一线激素治疗反应将急性GVHD分为敏感型、依赖型和难治型,评估后续慢性GVHD的发生率、危险因素和临床结局。结果显示激素依赖型和难治型急性GVHD是慢性GVHD发生的显著独立危险因素,而敏感型不是;激素依赖型后发生的慢性GVHD预后与难治型相似,并非介于难治型与敏感型之间。
要点
- 784例移植受者中347例(44%)发生急性GVHD,其中敏感型13%、依赖型12%、难治型19%。
- 慢性GVHD的3年累积发生率为25%。
- 激素依赖型和难治型急性GVHD是慢性GVHD发生的显著独立危险因素,敏感型不是。
核心结论
- 激素依赖型急性GVHD后发生的慢性GVHD预后与难治型相似,并非如假设那样介于难治型与敏感型之间。
- 既往急性GVHD治疗反应状态是慢性GVHD严重程度和结局的重要预测因素。
研究设计与样本
- 回顾性单中心队列研究,纳入2008至2016年间784例因血液系统恶性肿瘤接受异基因造血干细胞移植的成人和儿童连续病例。
- 按一线激素治疗反应将急性GVHD分为激素敏感型、激素依赖型和激素难治型,并与无急性GVHD病史者比较慢性GVHD的发生率、危险因素和临床结局。
主要发现
- 784例中347例(44%)发生急性GVHD,其中激素敏感型13%、激素依赖型12%、激素难治型19%。
- 慢性GVHD的3年累积发生率为25%。
- 发生慢性GVHD者中,39%无既往急性GVHD诊断;有既往急性GVHD诊断者中,16%为敏感型、24%为依赖型、21%为难治型。
- 轻度或中度慢性GVHD在既往激素依赖型急性GVHD者中最高,重度慢性GVHD在既往激素难治型急性GVHD者中最常见。
- 激素依赖型和难治型急性GVHD是异基因造血干细胞移植后发生慢性GVHD的显著独立危险因素,而激素敏感型急性GVHD不是危险因素。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chronic graft-versus-host disease (cGVHD) is a major limitation to the long-term success of allogeneic hematopoietic cell transplantation (HCT). Our prior study of acute GVHD (aGVHD) defined distinct treatment-response groups based on the response to first-line corticosteroids: steroid-sensitive (SS), steroid-resistant (SR), and steroid-dependent (SD) aGVHDs. We conducted a retrospective, single-institution, cohort study to assess the incidence, risk factors, and clinical outcomes of patients with cGVHD after a previous diagnosis of SS, SD, or SR aGVHD, compared with those with no history of aGVHD. Among 784 consecutive adult and pediatric recipients of HCT for hematologic malignancies between 2008 and 2016, 347 (44%) developed aGVHD, with 13% SS, 12% SD, and 19% SR aGVHD. The 3-year cumulative incidence of cGVHD was 25%. Among those with cGVHD, 39% had no prior aGVHD diagnosis, whereas among those with a prior aGVHD diagnosis, 16% had SS, 24% had SD, and 21% had SR aGVHD. Mild or moderate cGVHD was highest among those with preceding SD aGVHD, whereas severe cGVHD was most frequent among those with previous SR aGVHD. We identified SD and SR aGVHDs as significant independent risk factors for the development of cGVHD after allogeneic HCT, whereas SS aGVHD was not a risk factor. Our study demonstrates that cGVHD after SD aGVHD did not have an intermediate prognosis between SR and SS groups as hypothesized; rather, cGVHD after both SD and SR aGVHD have similar prognoses. Our findings suggest that previous aGVHD response states are important predictors of cGVHD severity and outcomes.
引用
- Herzog S, Weisdorf DJ, Shanley R, et al. Chronic GVHD after steroid-sensitive, -dependent, and -refractory acute GVHD: incidence and clinical outcomes. Blood Adv. 2023. PMID: 37036949. doi:10.1182/bloodadvances.2022009505
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。